P
About
Philip Scheltens is a Partner and Head of the Dementia Fund at EQT Life Sciences. He is listed as the responsible advisor for NewAmsterdam Pharma, a late-stage biopharmaceutical company focused on metabolic diseases and investigating obicetrapib as a potential treatment for Alzheimer’s disease.
Focus Areas
BioTech, HealthTech, Dementia
Verified Contact & Outreach Agent
Direct Professional Email Pattern
AI Outreach Agent Pitch Writer
Compose an personalized, high-converting outreach message targeting their exact investment interest...